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Summary 
The blood-brain barrier restricts the passage of many pharmacological agents into the brain pa- 
renchyma.  Bacterial  glycopeptides  induce  enhanced  blood-brain  barrier  permeability  when 
they are present in the subarachnoid space during meningitis. By presenting such glycopeptides 
intravenously,  blood-brain  barrier permeability in rabbits was enhanced  in a  reversible time- 
and dose-dependent  manner to agents  ~<20 kD in size. Therapeutic  application  of this bioac- 
tivity was evident as enhanced  penetration  of the antibiotic  penicillin  and the magnetic  reso- 
nance  imaging contrast  agent gadollnium-diethylene-triamine-pentaacetic  acid into  the  brain 
parenchyma. 
T 
he brain is sequestered from components circulating in 
blood by the blood-brain  barrier.  Tight junctions  be- 
tween juxtaposed endothelial  cells of cerebral capillaries se- 
verely restrict the passage of molecules from the blood into 
the brain, a property distinct from the fenestrated endothe- 
lium of peripheral vessels. The ability to reversibly perme- 
abilize  the  blood-brain  barrier would  greatly facilitate the 
delivery of intravenously applied agents of potential thera- 
peutic value for diseases of the central nervous system. It is 
recognized  that blood-brain  barrier permeability develops 
during the course of bacterial meningitis (1). We sought to 
determine  if current  advances  in  the  understanding  of the 
pathophysiology  of this  abnormality  in  meningitis  could 
suggest novel mechanisms  to  enhance  blood-brain  barrier 
permeability in a controlled manner. 
The bacterial  components  that induce  blood-brain  bar- 
rier permeability  during  meningitis  have been  extensively 
characterized  during  the  past  10 years.  One  such  compo- 
nent is endotoxin,  which induces a profound inflammatory 
response in the subarachnoid  space, including leukocytosis, 
brain  edema,  and  blood-brain  barrier permeability  (1).  In 
contrast, other components of the bacterial surface, particu- 
larly the glycopeptides derived from the bacterial cell wall, 
have been  found  to induce  only some components  of the 
symptom  complex  of meningitis,  the  entire  spectrum  of 
pathophysiology arising from a summation of several indi- 
vidual  activities  (2).  These  proinflammatory  components 
are monomers  or  multimers  of the  basic  disaccharide  tet- 
rapeptide (Tetra) 1 structure N-acetylglucosaminyl-N-acetyl- 
1Abbreviations used in  this paper: Gd-DTPA,  gadolinium-diethylene-tri- 
amine-pentaacetic acid; Pn, pneumococcal cell wall; Tetra, disaccharide 
tetrapeptide. 
muramyl-L-alanyl-D-glutamyl-diaminopimelyl (or lysyl)-D- 
alanyl-D-alanine.  Variations  in the peptide side chain con- 
tribute  to the  generation  of a  dozen  or more components 
in the cell wall of a given bacterium.  Intracisternal instilla- 
tion of purified glycopeptides induces enhanced permeabil- 
ity  of the  blood-brain  barrier,  allowing  influx  of serum 
proteins.  For some disaccharide tetra or tripeptides,  this ef- 
fect  occurs  without  engendering  other  pathological  ele- 
ments of meningitis,  such  as cerebral edema,  increased  in- 
tracranial  pressure,  or  recruitment  of leukocytes  (2).  We 
reasoned  that  intravenous  application  of this  subgroup  of 
simple  glycopeptides  might  induce  reversible blood-brain 
barrier permeability of potential therapeutic value. 
Materials and Methods 
Induction of Extravasation of Fluorescein-[abeled Dextrans into the 
Brain Parenchyma.  New Zealand white rabbits (2 kg; Hare Mar- 
land, Nutley, NJ) were injected intravenously with either 0.1 mg 
purified pneumococcal cell wall or 0.9% saline. FITC dextrans of 
4,  20,  40,  or 70 kD  (Sigma Immunochemicals, St.  Louis, MO) 
were given intravenously 1, 3,  5, 7, or 18 h  thereafter. Animals 
were then anaesthetized, and 30 rain later,  cerebrospmal fluid was 
collected  by  cisternal  puncture.  Animals  were  killed,  and  the 
lungs, liver, kidneys, spleen, heart, and brain were examined vi- 
suaUy  under  UV  light.  For  some  experiments,  animals  were 
treated with 1 mg/kg of antibody to IL-I c~ (Roche Laboratories, 
Nutley, NJ). 
Assessment of Blood-brain Barrier Permeability In  Vivo.  New 
Zealand white rabbits (2 kg) were placed into a stereotactic frame 
by a dental acrylic helmet (3) and injected intravenously with sa- 
line (negative control), 100 ~g Haemophilus influenzae cell wall, or 
100 I~g pneumococcal cell wall (Pn).  4.5 h later,  one of three ra- 
diolabeled  markers  was  introduced  intravenously:  14C-dextran 
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cose (150 I~Ci; Amersham), or [3H]penicillin (2 mCi; Merck Re- 
search Laboratories, Rahway, NJ).  30 min later, 200 ~1 of cere- 
brospinal fluid was withdrawn from the cistema magna, 50 Ixl of 
vitreous humor was removed from the anterior chamber of the 
eye, 1 ml ofheparinized blood was obtained by cardiac puncture, 
and  the  animals were  killed by  an  overdose  of pentobarbital. 
Within 5 rain, 1 g of the right parietal cortex was removed onto 
ice.  Brain samples  were  weighed,  homogenized,  in some  cases 
depleted of capillaries by centrifugation through dextran (4), and 
they were solubilized with Solvable (New England Nuclear, Bos- 
ton,  MA).  The  cpm in cerebrospinal fluid, ocular fluid, serum, 
and brain samples were determined. The amount of penetration 
of the radioactive marker into the whole brain was expressed as a 
ratio to the amount of tracer in serum (brain index). To distin- 
guish cpm in brain parenchyma versus that in blood in cerebral 
vessels, total brain cpm was corrected for the blood volume/gram 
brain by subtracting the  cpm/gram brain of control animals re- 
ceiving saline (n =  24). The Wilcoxon signed rank test was used 
for statistical  analysis against saline controls. 
Comparison of Purified Glycopeptide Activity.  Glycopeptides of 
H.  influenzae were purified by HPLC as described in detail else- 
where (2). The identity of each peak was confirmed by fast atom 
bombardment tandem mass spectrometry. All glycopeptides from 
the cell wall of H.  influenzae were tested by dividing the HPLC 
eluate into groups  1-6 according to the elution time. The main 
components of each fraction are listed in Table 2. Each compo- 
nent was  injected intravenously at  a  dose  corresponding to  its 
proportion in the highly active, whole-cell wall preparation. At 
4.5 h,  1 mCi of [3H]penicillin or 30 I~Ci of [14C]sucrose  (Amer- 
sham) was injected intravenously. 30 rain later, the penetration of 
radiolabel into  the  brain parenchyma was  assessed  as  indicated 
above. For the most active components, the Tetra and its variants, 
experiments were  repeated with purified material. Variations in 
dose and the relative time between challenge with Tetra (10 Ixg) 
and injection of the permeability marker was performed to estab- 
lish the magnitude and time course of enhanced permeability. 
Histopathology.  Rabbits received saline (control) or pneumo- 
coccal cell wall (1 rag) intravenously. 4.5 h later, horseradish per- 
oxidase (100,000 U; 500 rag; Signla) was injected intravenously. 
15 rain thereafter, the animal was euthanized and perfused with 
30(} ml of 3% glutaraldehyde in 0.1  M  sodium cacodylate buffer, 
pH 7.3. The brain, lung, and kidney were fixed in glutaraldehyde 
for 48  h,  sections were  cut and treated with diaminobenzidine, 
and electron microscopy was  performed by Dr. J.  Elroy  (Tufts 
University, Boston, MA). 
Magnetic Resonance Imaging.  Three  rabbits  were  challenged 
with 1 mg ofpneumococcal cell wall intravenously. 2 h later, the 
animals were anesthetized and the contrast agent gadolinium-di- 
ethylene-triamine-pentaacetic acid  (Gd-DTPA;  1.5  cc/kg)  was 
injected intravenously. Imaging was performed at the Small Ani- 
mal Magnetic Resonance Imaging Unit, Department of Radiol- 
ogy, New York Hospital-Cornell Medical Center for 15 rain ev- 
ery  hour  2-6  h  after  cell  wall  challenge.  Tl-weighted  images 
were compared over time for the appearance of enhancement as 
an indication of Gd-DTPA penetration across  the  blood-brain 
barrier. 
Results 
Induction  of Blood-Brain  Barrier Permeability  to Intravenous 
Markers.  To  assess  if intravenous  administration  of cell 
walls could induce blood-brain barrier permeability, rabbits 
were challenged intravenously with purified cell wall from 
one of two meningeal pathogens,  Gram-positive Streptococ- 
cus pneumoniae or Gram-negative H.  influenzae  (2,  3).  Sub- 
sequent passage  out of the vascular compartment of intra- 
venously applied  fluoresceinated  dextrans  of various  sizes 
was assessed visually as fluorescent staining of the brain pa- 
renchyma and cerebrospinal fluid (Table 1). Strong staining 
of brain by dextrans <40  kD in size was visible between 3 
and  7  h  after  the  cell  wall  challenge.  No  staining  was 
present  1  or  18  h  after  challenge.  Readministration  of a 
second dose of cell wall at 24 h  resulted in the same stain- 
ing 5 h  later as seen after a single dose, indicating no tachy- 
phylaxis.  Staining at 5  h  was  nearly completely eliminated 
by  coadministration of antibody to  IL-10~  with  cell  wall, 
suggesting that the  delay in onset of the permeability may 
result from a  dependence  on cytokine activity.  Enzymatic 
cleavage  of  the  Pn  so  as  to  dissociate  the  glycopeptide 
backbone from the stern peptides rendered the preparation 
inactive. Cerebrospinal fluid was stained sparingly; vitreous 
Table 1.  Induction  of Extravasation of Fluorescein-labeled Dextrans from Blood 
UV fluorescence 
Intravenous wall  lntracisternal wall 
Fluorescein dextran  Cerebral  Cerebrospinal  Ocular  Cerebral  Cerebrospinal 
marker  cortex  fluid  fluid  cortex  fluid 
4 kD  ++  +/-  +/-  ++  ++ 
20 kD  ++  +/-  -  ++  ++ 
40 kD  +/-  +/-  -  +  + + 
70 kD  ....  + 
Rabbits were injected intravenously with either 0.1 mg purified Pn or 0.9% saline. Intracisternally applied cell wall was used as a positive control. 
FITC dextran was given intravenously 5 h thereafter to correspond to the time of peak activity of the cell walls. 30 rain later, cerebrospinal fluid and 
ocular fluid samples were collected, animals were killed, and the lungs, liver, and kidneys, spleen, heart, and brain were examined visually under UV 
light. (n =  6-8 animals per group; n =  8 eyes per group) 
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Figure  1.  Penetration  of radiolabeled markers  into  the  brain  paren- 
chyma induced by cell walls. Rabbits were injected intravenously with sa- 
line (negative control),  100 Ixg H. influenzae cell wall (H/),  or 100 Ixg Pn. 
14C-dextran  or  [3H]glucose was introduced  intravenously. 30  rain  after 
marker injection,  1 g  of parietal cortex was excised, homogenized,  de- 
pleted of capillaries, and  the  radioactivity per gram of the  brain  paren- 
chyma was counted.  Each symbol represents an individual rabbit.  Hori- 
zontal lines indicate the  mean penetration of each marker.  Brain index: 
cpm per gram ofbrain/cpm per milliliter of serum. P  <0.01  for [3H]glu- 
cose marker with HI wall and Pn wall versus saline. 
humor obtained from the eye revealed no staining; kidneys 
demonstrated  occasional  patches  of  staining,  while  the 
heart,  lungs,  liver,  and  spleen  remained  negative.  Cere- 
brospinal fluid remained acellular with normal protein, glu- 
cose,  and  lactate  concentrations.  Brain  weights  and  light 
microscopic  histopathology  remained  normal,  indicating 
lack of cerebral edema (data not shown). This pattern con- 
trasted with that after intracisternal presentation of cell wall, 
which  induced  strong staining of brain  and  cerebrospinal 
fluid  together  with  profoundly  abnormal  cerebrospinal 
fluid  cytochemistry.  This  suggested  that  intravenous  cell 
wall could induce a transient enhancement of blood-brain 
barrier permeability, particularly to markers 20 kD or small- 
er in size,  without induction  of undesirable parameters of 
inflammation. Furthermore, the effects of the cell wall ap- 
peared to be topographically restricted to the cerebral mi- 
crovasculature. 
This observation was extended by documenting the en- 
hanced accumulation of intravenously applied  [3H]glucose 
but not 70-kD 14C-dextran in the brain parenchyma in an- 
imals  receiving  intravenous  cell  walls  of both  pathogens 
(Fig.  1). Accumulation of [3H]glucose was enhanced two- 
fold in the cell wall-treated groups (2.5-3.1% of serum con- 
centration was found in the brain),  as compared to saline- 
treated control animals (1.5% of serum value). The range of 
accumulation  was  similar  to  that  seen  in  animals  treated 
with RMP-7, a bradykinin agonist known to enhance up- 
take across the blood-brain barrier (5). 
Examination  of the  histopathology  associated  with  the 
permeability induced  by the pneumococcal cell wall indi- 
cated  a  significant  extravasation  of intravenously  applied 
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horseradish peroxidase into the brain parenchyma (Fig.  2). 
Examination  of the  tight junctions  at  the  cerebral  capil- 
lary level did not indicate passage of the marker between 
cells.  Rather, multiple pinocytotic vesicles were seen in cell 
wall-treated animals (Fig. 2, arrows); vesicles were very rare 
in control animals. Enhanced pinocytotic vesicle formation 
has  been  documented  to  contribute  to  enhanced  blood- 
brain barrier permeability in animals with experimental men- 
ingitis (6). 
Structure  Activity  Relationship  for  the  Ability  to  Increase 
Blood-brain  Barrier Permeability.  Of particular  therapeutic 
interest was the potential for a disaccharide peptide compo- 
nent of the cell wall to induce blood-brain barrier perme- 
ability similar to macromolecular cell wall.  These compo- 
nents  can not as yet be purified from pneumococcal wall. 
However, diverse cell wall subcomponents were separated 
and purified by HPLC from the peptidoglycan of H.  influ- 
enzae (2) and were tested for the ability to induce  [14C]su- 
crose  accumulation  in  the  brain  parenchyma  (Table  2). 
Several disaccharides linked  to  tetrapeptides  or tripeptides 
(groups 1 and 2) were active, increasing tbe penetration of 
the marker into brain by ~20% (2.7% of serum levels in sa- 
line group versus 3.3-3.5% in glycopeptide-treated groups). 
Modification of the amino acid composition of the peptide 
side  chain  was  permissible  for  induction  of blood-brain 
barrier permeability (Table 2), but multimerization or mod- 
ification  of  the  disaccharide  reduced  activity  consistent 
with a restricted structure-activity relationship. 
The induction of permeability by the Tetra was dose de- 
pendent  (Fig.  3), achieving a maximum of 4.5% of serum 
values,  i.e.,  approximately double  that  of saline  controls. 
This accumulation  occurred between 4  and  5  h  after cell 
wall  challenge,  after which  time  the  blood-brain  barrier 
permeability returned to baseline, confirming the transient 
nature of the enhanced permeability (Fig. 4). 
Enhancement  of  Penetration  of  Therapeutic  and  Imaging 
Agents  into the Brain.  To  examine a  therapeutic  applica- 
tion of the bioactivity of the cell wall components, the abil- 
ity to enhance penetration of the antibiotic penicillin into 
the  normal brain  was tested.  In the  absence of inflamma- 
tion, 3% of the peak serum concentration of penicillin can 
be detected in brain (serum peak occurs at 30 rain after in- 
travenous injection)  (Fig.  5).  Cell walls  and  active glyco- 
peptides resulted in between "-~20 and 250% enhancement 
in the accumulation of penicillin in brain with a maximum 
brain uptake of 8% of serum levels (Table 2 and Fig.  5).  Si- 
multaneous  measurement  of cerebrospinal  fluid  penicillin 
penetration  indicated  an enhancement from 6  +  1.3%  of 
serum levels in  control animals to 38  +  4% in  cell wall- 
treated animals. 
A  further possible application  of the  bioactivity of cell 
wall  on  blood-brain  barrier  permeability is  contrast  en- 
hancement  in  magnetic  resonance  imaging of the  central 
nervous  system.  The  magnetic  resonance  imaging  agent 
Gd-DTPA (7) is normally excluded from the brain paren- 
chyma. Imaging the brain hourly after intravenous cell wall 
challenge demonstrated Gd-DTPA enhancement over the 
cerebral  cortex.  Enhancement  began  at  4  h  and  became Figure 2.  Induction of penetration  of horseradish peroxidase into the brain parenchyma  by intravenous  cell wall. 4.5 h after intravenous  challenge  with 
saline or Pn, horseradish peroxidase was injected  intravenously.  15 rain thereafter, the animal  was killed, and the brain was fixed, cut, and treated with di- 
aminobenzidine.  (A and (~ Saline control animal at ￿  10,000 and ￿  15,000, respectively.  The open arrow indicates a pinocytotic  vesicle  not containing 
label. (B and D) Cell wall-treated  animal.  Filled  arrows indicate  pinocytotic  vesicles  containing  label  (top left) and accumulation  of label on the tissue side 
of the vascular cell barrier (bottom  left). Two red cells partially  occupy the intravascnlar  space. A long segment of intercellular  junction (pair of open arrow- 
heads) is shown to exclude label. 
prominent particularly in the region of the occipital cortex 
at 5 h after cell wall challenge (Fig. 6). 
Discussion 
Relatively  few  strategies  enhance  the  penetration  of 
therapeutic  agents  into  the  brain.  Successful  approaches 
have included covalent attachment of the agent to an anti- 
transferrin receptor antibody (4, 8), coadministration of the 
agent  with  antibacterial  antibodies  that  cross-react  with 
brain (10),  or  coadministration of the  agent with intraca- 
rotid administration of a ~2-bradykinin analogue, RMP-7 
(5). The intravenous application of a glycopeptide provides 
a potential simpler and readily reversible alternative to these 
more complex procedures. 
Strong staining of brain by fluoresceinated dextrans <~20 
kD in size was visible between 3 and 7 h  after the cell wall 
challenge. Permeability was confirmed by a doubling of the 
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Muropeptide  Structure  Brain index [3H]penicillin  Brain index [14C]sucrose 
Saline 
1. Tetra 
2. Tetra variants pooled 
A. Tetra (A/S) 
B. Tetra (G) 
C. Tri 
3. Tetra  ~r 
Tetra-Tri 
Tetra-Tetra(G) 
4. Tetra dimer 
5. Tetra dimer (Anh) 
6. Tetra trimer (Anh) 
GM-AIa-Glu- Dap-Ala 
(Tetra A/S, Tetra G, Tri) 
GM-Ala-Glu-Dap-Ser/Asp 
11.2  +  0.2 
13.0 +- 0.8* 
(0.002%) 
13.3  +  2.3  w 
(0.002%) 
ND 
GM-Ala-Glu-Dap-Gly  ND 
GM-Ala-Glu-Dap  ND 
2.75  +-_ 0.5 
3.28 +  0.8* 
(0.005%) 
ND 
3.43  +  0.7  w 
(0.005%) 
3.26 +  0.7 w 
(0.004%) 
3.53  -- 1.3 w 
(0.006%) 
GMnr-Ala-Glu-Dap-Ala 
GM-Ala-Glu-Dap 
I 
Ala-Da p-Glu-Ma-GM  10.8  +  1.8  ND 
GM-Ala-GIu-Dap-Gly 
I 
Ala-Dap-Glu- Ala-GM 
GM-Ma-GIu- Dap-Ma 
I 
Ma-Dap-Glu-Ala GM  11.1  +- 1.2  ND 
GM-Ala-Glu-Dap-Ma 
I 
Ala-Dap- GIu-Ala-GM (Anh)  11.6  +  1.8  ND 
GM-AIa-Glu- Dap-Ala 
I 
Ala-Dap-Glu-Ala-  GM  10.0  +  0.4  ND 
I 
GM(Anh)-Ala -Glu -Dap-Ala 
All glycopeptides from the cell wall ofH. influenzae  were tested for the ability to induce accumulation of [3H]penicillin in rabbit brain 5 h after chal- 
lenge (n/>4 animals per substance). The main components of fractions tested as groups 1~ are listed. Brain index: [cpm per gram ofbrain/cpm per 
milliliter of serum] ￿  100 +- SD. Values in parentheses are the percentage injected dose accumulating in brain above that of saline controls. Analysis 
of individual glycopeptides in Groups 1 and 2 was also performed with 30 ~Ci of p4C]sucrose according to the same protocol. ND, not determined. 
Significant difference from saline controls: *P =  0.04; *P =  0.05; w  of groups 2 A-C P =  0.02. GM, N-acetylglucosaminyl-N-acetyl- 
muramic acid; Anh, 1,6 anhydro GM; nr, nonreduced;  Dap, diaminopimelic acid. Amino acids  are designated by the conventional three-letter code. 
accumulation of [3H]glucose. The exclusion of larger mol- 
ecules, such as 70-kD dextran, was validated using radiola- 
beled material.  This  exclusion limit differs from  that  seen 
during bacterial meningitis, where  passage of albumin  (66 
kD)  and even larger molecular weight species >120  kD is 
markedly increased (10). Electron microscopic examination 
of the  cerebral  capillary endothelium  in  meningitis  indi- 
cates that two processes occur to enhance permeability: in- 
creased pinocytotic vesicle formation and loss of tight junc- 
tions  between  endothelial cells  (1,  6).  The  pathology of 
the effects of cell wall on cerebral capillaries differed from 
meningitis in that tight junctions remained intact while pi- 
nocytotic vesicle activity was  enhanced.  This suggests that 
the effect of cell walls may involve increasing transcellular 
transport ofintravascular components rather than induction 
of loosening of tight junctions  between  endothelial cells. 
Increased  trafficking,  as  opposed  to  physical  opening  of 
tight junctions,  would  be  compatable  with  the  observed 
preservation of restriction of penetration of larger molecu- 
lar weight species. 
The effect of cell walls appeared to be strong on the ce- 
rebral microvasculature, the site of the blood-brain barrier, 
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Figure 3.  Dosage effect on Tetra bioactivity.  Tetra was injected  intra- 
venously at the indicated  dose,  followed by 30  ~xCi of [14C]sucrose after 
4.5 h. Brain index =  cpm per gram brain/cpm per milliliter  serum +  SD; 
value of 4.4 for 2 Ixg Tetra is equivalent to 0.007%  of the injected  dose 
and differs from control at P <0.0I. 
as indicated by the  accumulation of label in  the  brain pa- 
renchyma. A  lesser effect was evident for penetration into 
cerebrospinal  fluid.  The  blood-brain  barrier  arises  at  the 
cerebral capillary endothelium,  while  the  barrier between 
blood and the subarachnoid space arises  at the level of the 
specialized epithelium of the choroid plexus. The continu- 
ity of interstitial fluid of the brain with cerebrospinal fluid 
may allow material  crossing the  cerebral  microvasculature 
to accumulate in the subarachnoid space. Although also de- 
lineated by tight junctions,  examination of the blood-ocu- 
lar barrier indicated no substantial enhancement of penetra- 
tion  of 20-kD  fluoresceinated  dextran  into  the  vitreous 
fluid of the eye. Furthermore, no staining of other periph- 
eral organs such as the lungs, spleen, liver, or kidneys were 
noted, suggesting that this effect is either limited to or most 
pronounced on endothelial cells of the central nervous sys- 
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Figure  4.  Time course of enhanced blood brain barrier permeability. 
Tetra (10 Ixg) was injected intravenously at 0 h in groups of five or more 
animals followed by an injection of 30 IxCi of [14C] sucrose at 4.5 h. Each 
symbol represents an individual  animal.  Brain  index  =  cpm per gram 
brain/cpm per milliliter  serum -+ SD. 
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Figure  5.  Penetration of pH]penicillin into the brain parenchyma in- 
duced by cell walls. Rabbits were challenged  with the indicated  cell wall 
as in Fig. 1. [3H] penicillin  was introduced intravenously at 4.5 h after cell 
wall.  Each symbol represents an individual  rabbit.  Horizontal lines  indi- 
cate  the mean penetration of each marker. Brain  index:  cpm per gram of 
brain/cpm per milliliter  of serum, P <0.001  for HI wall and Pn versus sa- 
line. 
tern.  Investigation of a possible receptor mediating this ef- 
fect will reveal if distribution  of receptor can  account  for 
differences in  the  biological activities of cell walls  at these 
different sites. 
The bioactivities of bacterial glycopeptides are numerous 
and depend  critically on  the  structure  of the  glycopeptide 
and  the  nature  of the  target eukaryotic cell.  For instance, 
modification  of the  disaccharide  moiety to  a  1,6  anhydro 
linkage  defines  the  sleep  peptide  known  to  induce  slow 
Figure 6.  Sagittal magnetic resonance image of a rabbit challenged  with 
Pn. The rabbit was anesthetized  and challenged  with 1 Ixg ofpneumococ- 
cal cell wall intravenously. 4 h later,  the contrast agent Gd-I)TPA was in- 
jected  intravenously, and imaging was performed for 15 nun every hour. 
The Tl-weighted image shown was acquired at 5 h. Nomial brain paren- 
chyma  excludes  Gd-DTPA  and  remains grey  (black  arrow).  Gd-DTPA 
penetration  through the blood-brain barrier results  in a white enhance- 
ment that is pronounced over the occipital  cortex in this image (open  ar- 
ww).  This image is representative  ofresuhs obtained in three animals. 
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while a lactyl-tetrapeptide  derivative is toxic to respiratory 
ciliated  cells  (12).  The  most active  structure  in  this  study 
was a disaccharide linked to three or four peptides.  The ac- 
tivity  of the  component  was  dose  dependent,  and  it  oc- 
curred in a strict time-dependent fashion, peaking at 4-5 h 
after dose.  In contrast to other known activities,  modifica- 
tion  of the  amino  acid  composition  of the  peptide  side 
chain was permissible  for induction of blood-brain barrier 
permeability,  but  multimerization  or  modification  of the 
disaccharide  reduced  activity  consistent  with  a  restricted 
structure-activity relationship. 
The magnitude  of the  enhanced accumulation of intra- 
venous marker in the brain parenchyma ranged from ~20 
to  250%.  Accumulation  of [3H]glucose in  the  brain  dou- 
bled  in  cell  wall-treated  animals  as  opposed  to  controls. 
This effect is similar to that seen with the same marker in 
animals treated with RMP-7,  a bradykinin agonist known 
to  enhance  uptake  across  the  blood-brain  barrier  (5).  In 
healthy individuals,  ,--~3% of peak serum concentrations of 
penicillin can be found in brain tissue.  This value increases 
to  ~15%  in  gravely ill  patients  with  bacterial  meningitis, 
characterized by severe breakdown of the blood-brain bar- 
rier and pathological brain edema, suggesting that this level 
of permeability may not be compatible with recovery. The 
glycopeptides applied here resulted in up to 8% of the se- 
rum  concentration  of penicillin  appearing  in  brain  tissue 
without apparent brain edema  or residual  neurological ef- 
fects  in  the  experimental  animals.  The  enhanced  perme- 
ability was  transient,  and  it indicates  that  the  blood-brain 
barrier can be permeabilized to this degree reversibly, with- 
out generation of brain edema. 
This enhanced level of penetration  ofpeniciUin  (0.002- 
0.01% of injected dose) is within  the 0.001-0.1%  range of 
penetration of an injected dose documented for some small 
peptides that cross well into the brain (13). Thus, small gly- 
copeptides may provide a new avenue for development of 
agents  useful  in  delivering  treatments  for  diseases  of the 
central  nervous system across  the  blood-brain barrier.  In- 
creasing  the  penetration  of an  antibiotic  into  the  brain 
could be  of therapeutic  importance when  efficacy is mar- 
ginal by conventional  dosing,  for example,  such  as  when 
fungi or resistant bacteria are the cause of central nervous sys- 
tem disease.  Greater impact of this type of therapeutic  ap- 
proach would most likely accrue through antitumor  ther- 
apy or imaging, as demonstrated in Fig. 6. 
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